Mentor to roll out PerImmune physician-office bladder cancer test kit this fall, CEO says.
This article was originally published in The Gray Sheet
Executive Summary
MENTOR TO BEGIN MARKETING PERIMMUNE PHYSICIAN OFFICE BLADDER CANCER TEST THIS FALL under a marketing agreement announced June 16 by Mentor Chairman and CEO Christopher Conway at a Piper Jaffray investment conference in Minneapolis. The pact provides Mentor with exclusive worldwide distribution rights to Rockville, Maryland-based PerImmune's urine-based immunoassay, which is intended for use in conjunction with cystoscopy to aid in the management of bladder cancer patients.